Caroline Seymour

Pamiparib plus surufatinib showed signals of activity with a largely hematologic adverse effect profile in patients with PARP-pretreated, platinum-resistant ovarian cancer.

Frontline maintenance with niraparib and bevacizumab showed efficacy and safety profiles that are in line with similar regimens in advanced ovarian cancer.

Cadonilimab plus lenvatinib showed promise as therapy for patients with advanced endometrial cancer and disease progression on prior platinum therapy.

PFS was extended with elacestrant vs SOC in pretreated, ER-positive, HER2-negative breast cancer, regardless of the level of ESR1 variant allele fraction.

PYX-201 has received fast track designation from the FDA for patients with recurrent or metastatic HNSCC following progression with chemoimmunotherapy.

Non-myeloablative HSCT with TLI/TBI/ATG conditioning was safe and active in eliciting immune quiescence and tolerance.

The UK Medicines and Healthcare Products Regulatory Agency has approved the kit for the preparation of gallium-68 gozetotide injection.

A low composite gene expression score was associated with improved outcomes in patients with mCRPC who received bavdegalutamide.

CUSP06 received fast track designation from the FDA for patients with platinum-resistant ovarian cancer.

The combination of seclidemstat and azacitidine will resume study in a phase 1/2 trial in patients with MDS and CMML following a partial clinical hold.